To include your compound in the COVID-19 Resource Center, submit it here.

MIM-D3: Phase III data

Top-line data from the double-blind, U.S. Phase III MIM-725 trial in 403 patients with dry eye syndrome showed that twice-daily 1% MIM-D3 significantly improved central corneal fluorescein staining

Read the full 286 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE